Can you take a GLP-1 if you have hypothyroidism?
Key takeaways
Dr. Linda's take
If you already live with an underactive thyroid, you have probably built a quiet daily ritual around it. The pill first thing, water only, a wait before coffee or breakfast. So when a GLP-1 enters the picture, a very reasonable worry follows. Will this new medicine undo the balance you and your clinician worked to find?
Here is the honest, reassuring frame. An underactive thyroid is not the thyroid problem the famous warning label is talking about, and it is not treated as a roadblock to these medicines. What is real, and worth understanding, is a timing and absorption question, because your thyroid pill is picky about absorption and these medicines gently slow digestion. None of what follows is a plan for your specific situation. It is the general picture, so you can bring good questions to the person who actually manages your care.
Is hypothyroidism a reason you cannot take a GLP-1?
For most people, an underactive thyroid is a manageable, well-understood condition, and it is not listed as a contraindication to this class of medicines. The cautions printed on the label point somewhere very specific, and that place is not everyday hypothyroidism.
A boxed warning for this drug class exists for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. That is a rare, often inherited cancer of the thyroid's C-cells, which is a different thing from an underactive gland that simply is not making enough hormone. One is about the risk of a particular tumor; the other is about a hormone level that a daily pill helps restore.
What does the boxed warning about thyroid cancer actually mean?
The warning traces back to animal studies. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. Based on that signal, the manufacturers drew a clear line about who the medicine is not for.
The prescribing information for semaglutide, sold as Wegovy, carries a boxed warning and states that it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. The prescribing information for tirzepatide, sold as Zepbound, carries the same boxed warning and states that it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
Read closely, the warning is about a specific cancer and a specific genetic syndrome. It is not a statement that an underactive thyroid rules you out. If you want the deeper version of this exact question, our explainer on whether a GLP-1 raises your risk of thyroid cancer walks through the evidence and the family-history piece in detail.
Can a GLP-1 change how your thyroid medication is absorbed?
This is the part that actually applies to most women on levothyroxine, and it comes down to plumbing and timing rather than danger.
The semaglutide label states that the medicine causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. The tirzepatide label states that the medicine delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.
Your thyroid pill is unusually sensitive to this. Evidence confirms the key role of the stomach as a prerequisite for efficient absorption of oral levothyroxine. When the stomach empties more slowly, the conditions that levothyroxine relies on can change. Modeling research suggests that GLP-1 receptor agonists can influence the pharmacokinetics of oral medications by delaying gastric emptying.
What does that mean in practice? In people already on a stable dose of levothyroxine, starting a GLP-1 receptor agonist may enhance levothyroxine absorption through delayed gastric emptying, and these changes may cause thyroid hormone over-replacement. In other words, the shift tends to point toward slightly more thyroid hormone reaching you, not less. That is exactly why lab monitoring matters, and it is a conversation for your prescriber rather than a change anyone should make on their own.
How do people on levothyroxine and a GLP-1 stay on track?
The reassuring theme is that this is a known and watchable interaction, not a hidden one. In one published case, thyroid stimulating hormone levels became suppressed after a patient on levothyroxine started subcutaneous semaglutide. In that report the care team caught the change with routine labs and adjusted from there.
So the general playbook clinicians tend to use looks like this. Keep the same careful habits around when the thyroid pill is taken. Expect thyroid labs to be rechecked as a GLP-1 is started and worked upward. Treat any new symptoms of too much or too little thyroid hormone, such as changes in energy, heart rate, or sleep, as a reason to check in rather than to guess.
The same slowed-digestion effect is also why some people notice more stomach-related side effects in the early weeks. Our overview of common GLP-1 side effects covers what tends to settle with time. And if you are still weighing whether one of these medicines fits your health picture, our eligibility quiz is a low-key first step.
The bottom line
An underactive thyroid, treated and stable, is not the thyroid issue the warning label is about, and on its own it does not close the door on these medicines. The genuine thing to respect is timing and absorption, since levothyroxine is finicky and these medicines slow the stomach. That is the kind of variable a clinician tracks with lab work while you keep your usual routine. Bring your full history and your questions to that visit, and let the person who knows your labs make the calls.
Frequently asked questions
Does having hypothyroidism mean I cannot take a GLP-1?
Not by itself. An underactive thyroid is not listed as a contraindication for this class of medicines. The label's caution is narrower than that. A boxed warning for this drug class exists for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Is the thyroid cancer warning about an underactive thyroid?
No. It concerns a specific and often inherited cancer, not a low-functioning gland. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. That animal signal is why the boxed warning exists, and it is a separate topic from everyday hypothyroidism.
Could a GLP-1 change how my levothyroxine works?
It can affect timing and absorption rather than the medicine itself. The semaglutide label states that the medicine causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Since levothyroxine is sensitive to absorption, thyroid labs are usually monitored when one of these medicines is added.
What direction does the thyroid change usually go?
It often points toward more hormone being absorbed, not less. In people already on a stable dose of levothyroxine, starting a GLP-1 receptor agonist may enhance levothyroxine absorption through delayed gastric emptying, and these changes may cause thyroid hormone over-replacement. A clinician watches for this with lab work and manages any adjustment.
Who should not take these medicines at all?
The clearest line is genetic and cancer-related, not thyroid-hormone-related. The prescribing information for semaglutide, sold as Wegovy, carries a boxed warning and states that it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Anyone with that personal or family history should share it with their clinician before starting.
References
1. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-19).
2. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-19).
3. Cardiovascular diabetology (2025). Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation. PubMed PMID 41444586. https://pubmed.ncbi.nlm.nih.gov/41444586/ (Accessed 2026-07-19).
4. Journal of the American Pharmacists Association : JAPhA (2024). Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report. PubMed PMID 38992739. https://pubmed.ncbi.nlm.nih.gov/38992739/ (Accessed 2026-07-19).
5. Pharmacotherapy (2025). GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. PubMed PMID 39989027. https://pubmed.ncbi.nlm.nih.gov/39989027/ (Accessed 2026-07-19).
6. Frontiers in endocrinology (2020). Levothyroxine Therapy in Gastric Malabsorptive Disorders. PubMed PMID 33584549. https://pubmed.ncbi.nlm.nih.gov/33584549/ (Accessed 2026-07-19).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-19.*
Keep reading
How much weight can you lose on retatrutide?
Retatrutide is investigational, but its phase 2 trial is striking · the highest 12-mg dose cut body weight a mean 24.2% at 48 weeks. Dr. Linda lays out the real numbers, the context against approved options, and why phase 2 results can still shift.
Can a GLP-1 lower heart disease risk after menopause?
The SELECT trial found semaglutide lowered major cardiovascular events by 20% in people with established heart disease and obesity without diabetes · but it was not a menopause trial, so Dr. Linda explains where the evidence is solid and where it is extrapolated.
Were Black and Latina women included in GLP-1 weight-loss trials?
Black and Latina women were enrolled in the major semaglutide and tirzepatide weight-loss trials, and subgroup analyses found the medicines worked across race and ethnicity · but non-white participants were under-represented relative to disease burden.
Does a GLP-1 lower testosterone in women with PCOS?
GLP-1 medicines are linked to a modest, mostly indirect drop in testosterone and free androgen index in women with PCOS, with the biggest shifts when paired with metformin. Dr. Linda explains the evidence and the honest limits.
How much muscle do you lose on a GLP-1, and can you get it back?
Some of the weight lost on a GLP-1 is muscle, not just fat. Dr. Linda Moleon, MD on how much lean mass the trials show, whether it comes back after stopping, and the two things that actually protect it.
Does Florida heat affect how you store your GLP-1?
Florida heat is real, and your GLP-1 pen has rules. Dr. Linda Moleon, MD lays out the exact refrigerator range, room-temperature limits, and discard windows straight from the Wegovy and Zepbound FDA labels, so your medication still works when you need it.